In small retrospective studies, vitamin D deficiency has been associated with primary non-response, non-remission, and durability of anti-TNF therapy.19–21 We sought to assess whether pretreatment 25-hydroxyvitamin D concentrations predicted primary non-response and non-remission to infliximab and adalimumab in patients with Crohn’s disease. The gene discussed is TNF; the disease is vitamin D deficiency.